Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy
about
The roles of protein expression in synaptic plasticity and memory consolidationMechanisms of disseminated cancer cell dormancy: an awakening fieldEMT, CTCs and CSCs in tumor relapse and drug-resistancePSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer6-Shogaol induces apoptosis in human leukemia cells through a process involving caspase-mediated cleavage of eIF2αMechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signallingThe role of PKR/eIF2α signaling pathway in prognosis of non-small cell lung cancerInhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesisLinking ER Stress to Autophagy: Potential Implications for Cancer Therapy.Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cellsDevelopment of antiproliferative phenylmaleimides that activate the unfolded protein response.Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3.Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells.Fucoidan induces cancer cell apoptosis by modulating the endoplasmic reticulum stress cascades.Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress.Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatmentTargeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myelomaSynergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cellsQuiescent fibroblasts are protected from proteasome inhibition-mediated toxicityHarnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.Salubrinal-Mediated Upregulation of eIF2α Phosphorylation Increases Doxorubicin Sensitivity in MCF-7/ADR Cells.Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia.Phosphorylation of eIF2α attenuates statin-induced apoptosis by inhibiting the stabilization and translocation of p53 to the mitochondriaRegulation of tumor cell dormancy by tissue microenvironments and autophagy.The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis.The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapiesInhibition of eIF2α dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells.Therapeutic targeting of cancer cell cycle using proteasome inhibitorsImplications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins.Translation factors and ribosomal proteins control tumor onset and progression: how?Translational regulator eIF2α in tumor.Cantharidin Induces Apoptosis Through the Calcium/PKC-Regulated Endoplasmic Reticulum Stress Pathway in Human Bladder Cancer Cells.Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.Polyphenon E(R), a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis.Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal.Synthesis and anticancer activity of the (R,S)-benzofused 1,5-oxathiepine moiety tethered to purines through alkylidenoxy linkers.High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors.
P2860
Q26825627-152C9726-5245-4AAD-9C58-89DB16AAF68EQ27027015-D2FDAFD5-BB4E-443B-BFC1-51384EDAF843Q28082935-61D94810-DEFE-458F-9BC2-B5AFCBE0AED6Q28267716-078FCEDF-053E-41FE-B8D7-1245344C1D67Q28394859-3DE55E32-4F24-4991-84B7-958C192E33ACQ28478858-83547A33-A333-4BCC-BD0E-03EA2FC9BFE5Q28742943-2A09A69B-C3E3-4ED4-9160-DDA46A92E4B6Q33503420-D01B0D2B-060E-4856-9379-A52D476E009AQ33633401-7DDB4084-0A58-4428-B0FF-592F25A604D1Q33712077-B2A913CD-6FF6-4FA0-B6E3-86BBC25E46D4Q33941523-D25EE394-A429-4EB2-BCD1-9ED17C713EE0Q33978937-D67C6AD6-29CF-4BAB-B969-FD53748524A8Q34009832-EF506E76-D5E8-4E43-959C-660A33209005Q34058325-706650F6-1804-4F70-BBE3-A0C46CED6CDFQ34215234-3B007E93-F115-4704-A081-4EDDD5201267Q34359570-8ACBE482-4FA4-40A4-A412-21ABBCC8FD02Q35005510-F1827496-B21C-4374-9F5C-ABA068FE8A43Q35579435-6F11ABEA-DB3F-41AC-84BD-72C0D244858CQ35663049-C62267C0-E8B7-4CF9-9355-CA5D614C9FF0Q35902345-12D330A1-DA7C-4AA3-9DF3-6BDB9AB5593EQ36121745-29574D72-CF0C-45E5-997E-AF144941DFB6Q36234472-332F5BCE-2203-466D-A265-B2B4B400B900Q36413767-28A7ADBE-C65D-4D76-85AA-1BED6A01D10BQ36591295-B512C608-9D75-4739-A1DD-476509BB5683Q36674887-F982F9D5-EC87-4FC3-9177-A01E30461595Q36684403-909ACDEB-6D95-4C3B-B671-FF221E056924Q36836555-2EE49B01-2D4A-4D69-9C72-F66BB2B895C0Q36917366-57D33A7E-69FB-4AAC-B942-A0C56C33F361Q37285838-8DB87495-834A-4385-805E-7E4C438ED508Q37620650-0FD08A1E-AC5B-4A35-8EC4-22E57EB7B078Q38069898-737EB2B7-73C6-4F9E-ADBD-5EECE43437E6Q38089906-BC436B5B-1840-454B-9724-BBF496BA42E0Q38104237-4795CDB4-342B-49D8-80B6-FEA260A4B81AQ38194482-E9C27373-4EAE-49D9-8929-37744207A12FQ38875817-608ED6B1-0989-4BEF-BEC5-55B9F1302E90Q38906685-56630CCE-1549-41F3-9797-BC22D62758D1Q39042808-349159B0-313B-4AC3-A6FB-A38D423F0E76Q39130783-EBACD04E-4EEF-4951-9770-BF1F73AC0F53Q39499289-1C13F87E-66FF-4328-84E3-5AFCF771E568Q39795457-24AB09E7-2E9C-46D8-9C2D-36933D9D27ED
P2860
Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of eIF2alpha dephos ...... g proteasome inhibitor therapy
@en
Inhibition of eIF2alpha dephos ...... proteasome inhibitor therapy.
@nl
type
label
Inhibition of eIF2alpha dephos ...... g proteasome inhibitor therapy
@en
Inhibition of eIF2alpha dephos ...... proteasome inhibitor therapy.
@nl
prefLabel
Inhibition of eIF2alpha dephos ...... g proteasome inhibitor therapy
@en
Inhibition of eIF2alpha dephos ...... proteasome inhibitor therapy.
@nl
P2860
P1433
P1476
Inhibition of eIF2alpha dephos ...... g proteasome inhibitor therapy
@en
P2093
Denis M Schewe
P2860
P304
P356
10.1158/0008-5472.CAN-08-3858
P407
P577
2009-02-03T00:00:00Z